Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects

Cuicui Lu, Duncan Wei, Yahui Zhang, Peng Wang, Wen ZhangFrontiers in Oncology 2021 · DOI

Abstract

Breast cancer is the most common malignancy among women worldwide, excluding non-melanoma skin cancer. It is now well understood that breast cancer is a heterogeneous entity that exhibits distinctive histological and biological features, treatment responses and prognostic patterns. Therefore, the identification of novel ideal diagnostic and prognostic biomarkers is of utmost importance. Long non-coding RNAs (lncRNAs) are commonly defined as transcripts longer than 200 nucleotides that lack coding potential. Extensive research has shown that lncRNAs are involved in multiple human cancers, including breast cancer. LncRNAs with dysregulated expression can act as oncogenes or tumor-suppressor genes to regulate malignant transformation processes, such as proliferation, invasion, migration and drug resistance. Intriguingly, the expression profiles of lncRNAs tend to be highly cell-type-specific, tissue-specific, disease-specific or developmental stage-specific, which makes them suitable biomarkers for breast cancer diagnosis and prognosis.

Introduction: The Need for Precision Biomarkers

Breast cancer remains a leading cause of cancer-related mortality among women, primarily due to its extreme heterogeneity. Different subtypes respond uniquely to treatments and present vastly different clinical outlooks. Traditional clinical biomarkers, such as Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3), often lack the necessary sensitivity and specificity for early detection and accurate prognosis.

Recent research has turned toward the "dark matter" of the genome: Long Non-Coding RNAs (lncRNAs). Once dismissed as "transcriptional noise" or "junk DNA," these transcripts—defined as being longer than 200 nucleotides without coding potential—are now recognized as master regulators of cellular processes. Because their expression is highly specific to certain cell types, disease stages, or developmental phases, they represent a significant opportunity for precision oncology.

Molecular Mechanisms of lncRNA Function

LncRNAs exert their influence through diverse molecular pathways in both the nucleus and the cytoplasm. As synthesized from a decade of high-throughput and next-generation sequencing (NGS) research, their primary modes of action include:

  • Epigenetic Regulation: Altering DNA methylation or histone modification to control gene expression.
  • Molecular Scaffolding: Acting as a bridge to bring proteins together, forming functional complexes.
  • mRNA Alternative Splicing: Influencing how exons are joined during mRNA maturation.
  • miRNA Sponging: Functioning as "competitive endogenous RNAs" (ceRNAs) that sequester microRNAs, preventing them from silencing target mRNAs.
  • mRNA Stability and Post-translational Modification: Directly interacting with transcripts or proteins to modulate their lifespan and activity.
  • Small Peptide Encoding: Emerging evidence suggests some "non-coding" RNAs may actually encode functional micro-peptides.
Molecular mechanisms of lncRNAs in the nucleus and cytoplasm.

Clinical Utility: Diagnosis and Prognosis

The clinical appeal of lncRNAs lies in their unique properties:

  1. High Specificity: Unlike many protein markers, lncRNA expression is often restricted to specific tissues or breast cancer subtypes (e.g., Triple-Negative Breast Cancer), allowing for more granular diagnosis.
  2. Stability in Biofluids: lncRNAs remain remarkably stable in blood plasma, urine, and saliva. This stability makes them ideal candidates for non-invasive "liquid biopsies," which could supplement or even replace invasive tissue biopsies.
  3. Dual Regulatory Roles: lncRNAs are categorized based on their expression in tumors:
  4. Oncogenic (e.g., MALAT1, HOTAIR): Frequently upregulated, these promote metastasis, angiogenesis, and drug resistance.
  5. Tumor Suppressive (e.g., MEG3, XIST): Often downregulated; their loss removes critical "brakes" on tumor growth and proliferation.

Key Biomarkers and Clinical Outcomes

Several lncRNAs have emerged as frontrunners for clinical application. For instance, high serum levels of MALAT1 are significantly more prevalent in breast cancer patients compared to those with benign disease, and its high expression correlates with poor Overall Survival (OS) and Disease-Free Survival (DFS). Similarly, H19 plasma levels correlate with lymph node metastasis and hormone receptor status.

Summary of dysregulated lncRNAs in breast cancer and their clinical implications.

The future of lncRNA diagnostics likely lies in "biomarker panels." Combining multiple lncRNAs, or pairing them with traditional protein markers, significantly enhances diagnostic accuracy. For example, a panel combining lncRNA ANRIL with CEA has shown superior specificity compared to either marker alone in other cancers, a strategy now being explored for breast cancer.

Challenges and Future Directions

Despite their immense promise, several hurdles must be cleared before routine clinical deployment:

  • Detection Sensitivity: Circulating lncRNAs often exist at very low concentrations, requiring highly sensitive detection methods beyond standard spectrophotometry.
  • Biological Conservation: lncRNAs often lack primary sequence conservation across species, complicating the translation of findings from animal models to human trials.
  • Off-Target Effects: Therapeutic strategies targeting lncRNAs (via CRISPR or RNA interference) must be carefully designed to avoid perturbing essential genes.
  • Standardization: There is a critical need for standardized protocols regarding sample collection, processing, and data normalization to ensure reproducible clinical results.

In conclusion, lncRNAs represent a transformative class of biomarkers that could redefine breast cancer management through improved diagnostic precision and prognostic accuracy.

Summary updated

Abstract

Breast cancer is the most common malignancy among women worldwide, excluding non-melanoma skin cancer. It is now well understood that breast cancer is a heterogeneous entity that exhibits distinctive histological and biological features, treatment responses and prognostic patterns. Therefore, the identification of novel ideal diagnostic and prognostic biomarkers is of utmost importance. Long non-coding RNAs (lncRNAs) are commonly defined as transcripts longer than 200 nucleotides that lack coding potential. Extensive research has shown that lncRNAs are involved in multiple human cancers, including breast cancer. LncRNAs with dysregulated expression can act as oncogenes or tumor-suppressor genes to regulate malignant transformation processes, such as proliferation, invasion, migration and drug resistance. Intriguingly, the expression profiles of lncRNAs tend to be highly cell-type-specific, tissue-specific, disease-specific or developmental stage-specific, which makes them suitable biomarkers for breast cancer diagnosis and prognosis.
BibTeX
@inproceedings{lu2021long,
  author = {Cuicui Lu and Duncan Wei and Yahui Zhang and Peng Wang and Wen Zhang},
  title = {{Long Non-Coding RNAs as Potential Diagnostic and Prognostic Biomarkers in Breast Cancer: Progress and Prospects}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.710538},
}
Figure